World Health Organization classification and nomenclature of ovarian cancer
- PMID: 1234636
World Health Organization classification and nomenclature of ovarian cancer
Abstract
A World Health Organization (WHO) committee of representatives from seven nations published a histologic typing of ovarian tumors in 1973. Their typing of common epithelial tumor was based largely on the classification by the International Federation of Gynaecology and Obstetrics (FIGO), and the single most important concept to emerge from the FIGO and WHO classifications was the distinction among common epithelial tumors between tumors of borderline malignancy and carcinomas. A second general category of ovarian tumors, some of which are clinically malignant, was designated by the WHO committee as sex cord-stromal tumors (neoplasms containing granulosa, theca, collagen-producing stromal, Sertoli, and/or Leydig cells). The WHO classification of germ cell tumors emphasized the necessity of careful examination of the gross specimen with jucicious sampling for microscopic evaluation. The classification and nomenclature used within an institution should be the one most conductive to mutual understanding and optimal patient care; however, when that nomenclature has to be translated into one with more widespread acceptance, the WHO classification, based on the earlier and widely adopted classification of FIGO, is presently the most deserving of universal usage.
Similar articles
-
Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.Mod Pathol. 2005 Feb;18 Suppl 2:S81-98. doi: 10.1038/modpathol.3800311. Mod Pathol. 2005. PMID: 15502809 Review.
-
[Histological classification in 10 288 cases of ovarian malignant tumors in China].Zhonghua Fu Chan Ke Za Zhi. 2002 Feb;37(2):97-100. Zhonghua Fu Chan Ke Za Zhi. 2002. PMID: 11953074 Chinese.
-
Histological classification of ovarian cancer.Med Electron Microsc. 2003 Mar;36(1):9-17. doi: 10.1007/s007950300002. Med Electron Microsc. 2003. PMID: 12658347 Review.
-
[Surgical pathology of ovarian tumors].Hokkaido Igaku Zasshi. 1995 Jan;70(1):41-55. Hokkaido Igaku Zasshi. 1995. PMID: 7744370 Review. Japanese.
-
From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.Adv Anat Pathol. 2007 May;14(3):149-77. doi: 10.1097/PAP.0b013e3180504abf. Adv Anat Pathol. 2007. PMID: 17452813 Review.
Cited by
-
Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.Oncoimmunology. 2015 Jan 7;3(12):e962397. doi: 10.4161/21624011.2014.962397. eCollection 2014 Dec. Oncoimmunology. 2015. PMID: 25964862 Free PMC article.
-
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.Mol Cancer Ther. 2012 Feb;11(2):360-9. doi: 10.1158/1535-7163.MCT-11-0400. Epub 2011 Dec 5. Mol Cancer Ther. 2012. PMID: 22144664 Free PMC article.
-
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.Hum Cell. 2013 Sep;26(3):121-7. doi: 10.1007/s13577-013-0062-y. Epub 2013 Feb 21. Hum Cell. 2013. PMID: 23430509
-
Clinical significance and biological role of Wnt10a in ovarian cancer.Oncol Lett. 2017 Dec;14(6):6611-6617. doi: 10.3892/ol.2017.7062. Epub 2017 Sep 26. Oncol Lett. 2017. PMID: 29163692 Free PMC article.
-
Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers.PLoS One. 2025 May 20;20(5):e0322744. doi: 10.1371/journal.pone.0322744. eCollection 2025. PLoS One. 2025. PMID: 40392873 Free PMC article.